Capital Medical Center
Click Here to Subscribe!

E-Health Services

Daily Health News

  Latest News
  FDA Approvals
  FYI

Health Information

Newsletter Topics

Alzheimer's Disease
Anxiety
Arthritis
Blood Pressure
Breast Cancer
Cancer
Depression
Diabetes
Exercise / Fitness
Female Urological Disorders
Gastrointestinal Health
Healthy Diet
Heart Disease
Men's Health
Menopause
Neurology
Orthopedics
Pain Management
Parenting
Pediatrics
Pregnancy
Senior Caregiving
Seniors' Health
Sleep Disorders
Sports Medicine
Stroke
Weight Management
Women's Health
Women's Heart Health
Username: Password: Forgot password?
Remember me next time.
 FDA Approvals
Return to
Daily Health Main Page.
  Tweet it! Pin it!
  Trulance Approved for Chronic Constipation
 
Drug designed to stimulate upper gastrointestinal tract

 

FRIDAY, Jan. 20, 2017 (HealthDay News) -- Trulance (plecanatide) has been approved by the U.S. Food and Drug Administration to treat persistent constipation of unknown (idiopathic) cause in adults.

Some 42 million people in the United States are affected by constipation, according to the National Institutes of Health. Once-daily Trulance is designed to stimulate the upper gastrointestinal tract to secrete fluid and "support regular bowel function," the FDA said in a news release.

The oral drug was evaluated in two 12-week clinical studies involving a total of 1,775 adults with chronic constipation.

Diarrhea was the most common side effect. If diarrhea becomes severe, users should stop taking Trulance and contact a doctor, the FDA advised.

Trulance is produced by New York City-based Synergy Pharmaceuticals.

More information

Visit the FDA to learn more about this approval.

 
 
 
 
   More  FDA Approvals
 
   •  Siliq Approved for Plaque Psoriasis
  Injected drug is for use by patients who've failed other treatments
 
   •  Emflaza Approved for Duchenne Muscular Dystrophy
  First U.S. approval of corticosteroid to treat the disorder
 
   •  Newborn Screening Tests Approved
  The screens are used to detect four rare metabolic disorders
 
   •  Ovarian Cancer Drug Given Fast-Track Approval
  Rubraca's use is specific to women with a mutation of the BRCA gene, FDA said
 
Health Content Provided By:
The health content is provided for informational and educational purposes. It is intended for the general population and may not reflect specific conditions or risk of an individual or segment of the population. Therefore, it is not intended to be a substitute for professional medical advice, consultation, treatment or diagnosis. Always seek the advice of your physician or other qualified health provider with questions. Never disregard professional medical advice or delay in seeking it because of information obtained through these services.
E-Home | E-Health Services | Sample News | Subscribe | Feedback | Contact Us | Privacy Policy | Terms & Conditions
 
© 2010 CAPITAL MEDICAL CENTER · 3900 CAPITAL MALL DRIVE SW · OLYMPIA, WA 98502 · 360-754-5858 · SITEMAP · PRIVACY POLICY · TERMS & CONDITIONS
 
ABOUT US SERVICES & TECHNOLOGY FOR PATIENTS & GUESTS FOR PHYSICIANS FOR EMPLOYEES COMMUNITY CAREERS